
    
      The study is conducted during several visits or telephone follow-ups at the clinic over a
      period of 12 months and each patient receives a maximum of two treatments with MiraDry® (at
      3-month intervals). 100 participants are planned to participate in the study.

      The primary objective is to evaluate the effectiveness of the miraDry ® treatment measured by
      Hyperhidrosis Disease Severity Scale(HDSS).

      Secondary objectives are to evaluate the side effects and the quality of Life by assessment
      of The Dermatology life Quality Index, The Hyperhidrosis Quality of Life Index, and Hospital
      Anxiety and Depression Scale.
    
  